Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene

Mario T. Schellenberger; Sophie Farinelle; Stéphanie Willième; Claude P. Muller

doi:10.4161/hv.7.0.14579

Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene

Mario T. Schellenberger, Sophie Farinelle, Stéphanie Willième, Claude P. Muller^*

^*Corresponding author for this work

Department of Infection and Immunity

Research output: Contribution to journal › Article › Research › peer-review

15 Citations (Scopus)

Abstract

We have recently developed an experimental vaccine based on benzo[a]pyrene (B[a]P) conjugated to tetanus toxoid as a carrier protein. In combination with Freund adjuvant, this vaccine induces high levels of B[a]P-specific antibodies to protect against detrimental effects of this carcinogen. Here we evaluate this conjugate vaccine by replacing Freund adjuvant by adjuvants that are potentially compatible with their use in humans. We showed that all adjuvants tested induced specific antibodies against B[a]P and 7,8-diol-B[a]P, its carcinogenic metabolite. The best antibody levels were obtained with Quil A, MF-59 and Alum. Biological activity in terms of enhanced retention of B[a]P was confirmed in mice immunized with Quil A, Montanide, Alum and MF-59. Our findings demonstrate that a vaccination against B[a]P is feasible in combination with adjuvants licensed in humans.

Original language	English
Pages (from-to)	166-173
Number of pages	8
Journal	Human Vaccines
Volume	7
Issue number	SUPPL.
DOIs	https://doi.org/10.4161/hv.7.0.14579
Publication status	Published - Jan 2011

Keywords

Adjuvant
Benzo[a]pyrene
Hapten specific antibodies
Vaccine

Access to Document

10.4161/hv.7.0.14579

Cite this

@article{bf74a39de10c4d9bbfb332d59e6a79db,

title = "Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene",

abstract = "We have recently developed an experimental vaccine based on benzo[a]pyrene (B[a]P) conjugated to tetanus toxoid as a carrier protein. In combination with Freund adjuvant, this vaccine induces high levels of B[a]P-specific antibodies to protect against detrimental effects of this carcinogen. Here we evaluate this conjugate vaccine by replacing Freund adjuvant by adjuvants that are potentially compatible with their use in humans. We showed that all adjuvants tested induced specific antibodies against B[a]P and 7,8-diol-B[a]P, its carcinogenic metabolite. The best antibody levels were obtained with Quil A, MF-59 and Alum. Biological activity in terms of enhanced retention of B[a]P was confirmed in mice immunized with Quil A, Montanide, Alum and MF-59. Our findings demonstrate that a vaccination against B[a]P is feasible in combination with adjuvants licensed in humans.",

keywords = "Adjuvant, Benzo[a]pyrene, Hapten specific antibodies, Vaccine",

author = "Schellenberger, {Mario T.} and Sophie Farinelle and St{\'e}phanie Willi{\`e}me and Muller, {Claude P.}",

note = "Funding Information: The authors acknowledge the financial support of the Fond National de la Recherche (Tobavac project, FNR: 01/04/11, TR-PHD-BFR06-081), of the CRP-Sant{\'e} (REC-LNSI-20091206) and the Ministry of Health of Luxembourg (BFR06-081). We are also grateful to Dr. Thomas Kaminsky and Prof. Gilbert Kirsch (University Metz) for the chemical synthesis of the B[a]P-butyric acid and Dr. Tom Bechet for the B[a]P-BA conjugation.",

year = "2011",

month = jan,

doi = "10.4161/hv.7.0.14579",

language = "English",

volume = "7",

pages = "166--173",

journal = "Human Vaccines",

issn = "1554-8600",

publisher = "Landes Bioscience",

number = "SUPPL.",

}

TY - JOUR

T1 - Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene

AU - Schellenberger, Mario T.

AU - Farinelle, Sophie

AU - Willième, Stéphanie

AU - Muller, Claude P.

N1 - Funding Information: The authors acknowledge the financial support of the Fond National de la Recherche (Tobavac project, FNR: 01/04/11, TR-PHD-BFR06-081), of the CRP-Santé (REC-LNSI-20091206) and the Ministry of Health of Luxembourg (BFR06-081). We are also grateful to Dr. Thomas Kaminsky and Prof. Gilbert Kirsch (University Metz) for the chemical synthesis of the B[a]P-butyric acid and Dr. Tom Bechet for the B[a]P-BA conjugation.

PY - 2011/1

Y1 - 2011/1

N2 - We have recently developed an experimental vaccine based on benzo[a]pyrene (B[a]P) conjugated to tetanus toxoid as a carrier protein. In combination with Freund adjuvant, this vaccine induces high levels of B[a]P-specific antibodies to protect against detrimental effects of this carcinogen. Here we evaluate this conjugate vaccine by replacing Freund adjuvant by adjuvants that are potentially compatible with their use in humans. We showed that all adjuvants tested induced specific antibodies against B[a]P and 7,8-diol-B[a]P, its carcinogenic metabolite. The best antibody levels were obtained with Quil A, MF-59 and Alum. Biological activity in terms of enhanced retention of B[a]P was confirmed in mice immunized with Quil A, Montanide, Alum and MF-59. Our findings demonstrate that a vaccination against B[a]P is feasible in combination with adjuvants licensed in humans.

AB - We have recently developed an experimental vaccine based on benzo[a]pyrene (B[a]P) conjugated to tetanus toxoid as a carrier protein. In combination with Freund adjuvant, this vaccine induces high levels of B[a]P-specific antibodies to protect against detrimental effects of this carcinogen. Here we evaluate this conjugate vaccine by replacing Freund adjuvant by adjuvants that are potentially compatible with their use in humans. We showed that all adjuvants tested induced specific antibodies against B[a]P and 7,8-diol-B[a]P, its carcinogenic metabolite. The best antibody levels were obtained with Quil A, MF-59 and Alum. Biological activity in terms of enhanced retention of B[a]P was confirmed in mice immunized with Quil A, Montanide, Alum and MF-59. Our findings demonstrate that a vaccination against B[a]P is feasible in combination with adjuvants licensed in humans.

KW - Adjuvant

KW - Benzo[a]pyrene

KW - Hapten specific antibodies

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84855730847&partnerID=8YFLogxK

U2 - 10.4161/hv.7.0.14579

DO - 10.4161/hv.7.0.14579

M3 - Article

C2 - 21245662

AN - SCOPUS:84855730847

SN - 1554-8600

VL - 7

SP - 166

EP - 173

JO - Human Vaccines

JF - Human Vaccines

IS - SUPPL.

ER -

Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this